Cefoxitin
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Cefoxitin".

Cefoxitin
Systematic (IUPAC) name
(6S,7R)-4-(carbamoyloxymethyl)-7-methoxy- 8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia- 1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Identifiers
CAS number	35607-66-0
ATC code	J01DC01
PubChem	37194
Chemical data
Formula	C16H17N3O7S2
Mol. mass	427.454 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	minimal
Half life	41-59 min
Excretion	85% urine
Therapeutic considerations
Pregnancy cat.	B
Legal status
Routes	IV

Cefoxitin is a cephamycin antibiotic developed by Merck & Co., Inc., often grouped with the second−generation cephalosporins. It is also known as Mefoxin.

Microbiology

Cefoxitin acts by interfering with cell wall synthesis. Its activity spectrum includes a broad range of gram-negative and gram-positive bacteria including anaerobes. It is inactive in vitro to most strains of Pseudomonas aeruginosa and enterococci and many strains of Enterobacter cloacae. Staphlococci resistant to methicillin/oxacillin should be considered resistant to cefoxitin. ^[1]

References

1. ^ Mefoxin Official FDA information at Drugs.com

This antibiotic-related article is a stub. You can help Wikipedia by expanding it.